Jane Osbourn

Dr. Osbourn is an internationally recognized scientist and researcher. Prior to joining Alchemab, Dr. Osbourn served as Vice President of R&D at MedImmune, the biologics arm of AstraZeneca, where she contributed to the development of antibody phage display technology, authored key publications and patents and contributed to the discovery and development of a number of marketed antibody therapies including Humira and Durvalumab.

Additionally, Dr. Osbourn chairs the Cambridge-based cell therapy company Mogrify, serves as a Director of Babraham Bioscience Technologies, and Cambridge Enterprise, and is a member of the Crick Translational Advisory Group. Previously, she served as a Member of the UK Medical Research Council Industry Grant Award Assessment Panel, and from 2015-2019, Dr. Osbourn served as Chair of the Board of Directors of the UK BioIndustry Association.

In 2019 Dr. Osbourn was awarded an Order of the British Empire (OBE) in the Queen’s birthday honors for services to drug discovery, development and biotechnology. Additionally, in 2019, Dr. Osbourn was awarded the 2019 Scrip Lifetime Achievement Award for contribution to the pharma industry, and in 2021 was elected as a Fellow of the Academy of Medical Sciences.

Dr. Osbourn holds a BA in Natural Sciences (First Class: Biochemistry) from the University of Cambridge and a PhD from the John Innes Centre for Plant Science Research in Norwich.